21st Century treatment of diabetic retinopathy

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 5, 2007, Pages 623-631

  Chibber, Rakesh ^a   Cibber, Surina ^b   Kohner, Eva M ^b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aldose reductase; Anti inflammatory; Corticosteroids; Diabetic macular edema; Diabetic retinopathy; Growth hormone; Laser photocoagulation; protein kinase C; Triamcinolone acetonide; Vitrectomy

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; ANTILIPEMIC AGENT; ARI 809; BENFOTIAMINE; BEVACIZUMAB; CANDESARTAN; CANDESARTAN HEXETIL; CARBOXYLIC ACID; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUOCINOLONE ACETONIDE; GLUCOSE; HYALURONIDASE; HYDANTOIN; INSULIN; MINOCYCLINE; OCTREOTIDE; PEGAPTANIB; PLACEBO; PLASMIN; PYRIDAZINONE DERIVATIVE; RANIBIZUMAB; RUBOXISTAURIN; SORBINIL; SPIROSUCCINAMIDE; SUCCINIC ACID DERIVATIVE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; BLINDNESS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG MEGADOSE; EYE INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHYSECTOMY; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; LASER COAGULATION; LASER SURGERY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT INDICATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 34648828044     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.5.623     Document Type: Review

References (64)

1. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int. J. Clin. Pract. 60(11). 1471-1483 (2006).
2. Wilkinson CP, Ferris FL, Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9), 1677-1682 (2003).
3. Jain A, Sarraf D, Fong D. Preventing diabetic retinopathy through control of systemic factors. Curr. Opin. Ophthalmol. 14(6), 389-394 (2003).
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
5. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 837-853 (1998).
6. Funatsu H. Yamashita H. Pathogenesis of diabetic retinopathy and the renin - angiotensin system. Ophthalmic Physiol. Opt. 23(6). 495-501 (2003).
7. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risk of progression of retinopathy and visual loss related to tight control of blood pressure in Type 2 diabetes mellitus. UKPDS 69. Arch. Ophthalmol. 122(11), 1631-1640 (2004).
8. Sheth HG, Aslam S, Davies N. Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. Br. Med. J. 332(7552), 1272-1273 (2006).
9. Sjolie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res. Clin. Pract. 76 (Suppl. 1), S31-S39 (2007).
10. Lang GE. Laser treatment of diabetic retinopathy. Dev. Ophthalmol. 39, 48-68 (2007).
11. Yi Q, Bamroongsuk P, McCarty DJ, Mukesh BN, Harper CA. Clinical outcomes following laser photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital. Clin. Experiment. Opthalmol. 31(4), 305-309 (2003).
12. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologia 221(2), 95-102 (2007).
13. Lewis H. Role of vitrectomy in the treatment of diabetic macular edema. Am. J. Ophthalmol. 13(1), 123-125 (2001).
14. Kuppermann BD, Thomas EL, de Smet MD, Gritione LR. Vitrase® for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injectin of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 140(4). 573-584 (2005).
15. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase® for Vitreous Hemorrhage Study Groups. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am. J. Ophthalmol 140(4), 585-597 (2005).
16. Trese MT. Enzymatic-assisted vitrectomy. Eye 16(4), 365-368 (2002).
17. Sakuma T, Tanaka M, Mizota A et al. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest. Ophthalmol. Vis. Sci. 46(9), 3295-3299 (2005).
18. Setter SM, Campbell RK, Cahoon CJ. Biochemical pathways for microvascular complications of diabetes mellitus. Ann. Pharmacother. 37(12), 1858-1866 (2003).
19. Frank RN. Diabetic retinopathy. N. Engl. J. Med. 350(1), 48-58 (2004).
20. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr. Drug Targets 6(4), 475-86 (2005).
21. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55(10), 2757-2762 (2006).
22. Lang GE. Treatment of diabetic retinopathy with protein kinase C subtype B inhibitor. Dev. Ophthalmol. 39, 157-165 (2007).
23. Idris I, Donnelly R. Protein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab. Vasc. Dis. Res. 3(3). 172-178 (2006).
24. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54 (7), 2188-2197 (2005).
25. Aiello LP, Davis MD, Girach A et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113(12), 2221-2230 (2006).
26. Pomero F, Allione A, Beltramo E et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 46(3), 416-419 (2003).
27. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9(3), 294-299 (2003).
28. Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54(5), 1559-1565 (2005).
29. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr. Diabetes Rev. 3(1), 3-14 (2007).
30. Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18(12), 1450-1452 (2004).
31. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br. J. Ophthalmol. 86(4), 363-365 (2002).
32. Joussen AM, Poulaki V, Mitsiades N et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-suppression. FASEB J. 16(3), 438-440 (2002).
33. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56(2), 337-345 (2007).
34. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol. Metab. Clin. North Am. 31(3), 779-793 (2002).
35. Kohner EM. Aspirin for diabetic retinopathy. Br. Med. J. 327(7423), 1060-1061 (2003).
36. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113(9), 1533-1538 (2006).
37. Lam DS, Chan CK, Mohamed S et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol. 91(2), 199-203 (2007).
38. Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev. Ophthalmol. 39, 96-110 (2007).
39. Pearson P, Levy B; Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. Program and abstracts of the Association for Research in Vision and Ophthalmology 2005 Annual Meeting, FL, USA (2005) (Abstract 4673).
40. Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125(3), 309-317 (2007).
41. Jaffe GJ. Update on pharmacologic treatment of diabetic macular edema. Retina Today 2, 49-54 (2006).
42. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II Type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. Suppl. 24(1), S73-S80 (2006).
43. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol. 38(5-6), 752-765 (2006).
44. Sjolie AK, Porta M, Parving HH, Bilous R, Klein R. The DIRECT Programme Study Group. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J. Renin Angiotensin Aldosterone Syst. 6(1). 25-32 (2005).
45. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am. 19(3), 335-344 (2006).
46. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol. 90, 1542-1547 (2006).
47. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug Targets 6(4). 511-5124 (2005).
48. Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci. 1082, 151-171 (2006).
49. Cunningham ET Jr, Adamis AP, Altaweel MJ et al.; Macugen Diabetic Retinopathy Study Group. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10), 1747-1757 (2005).
50. Adamis AP, Altaweel M, Bressler NM et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113(1), 23-28 (2006).
51. Yang JC, Haworth L, Sherry RM et al. Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
52. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(10), 1695-1705 (2006).
53. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging 36(4), 331-335 (2005).
54. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3), 363-372 (2006).
55. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113(10), 1706-1712 (2006).
56. Sherris D. Ocular drug development - future directions. Angiogenesis 10(2), 71-76 (2007).
57. Jager RD, Aiello LP, Patel SC. Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 24(5), 676-698 (2004).
58. Kupperman BD. Transcleral uptake and diffusion of bevacizumab (Avastin) and ranibizumab (Lucentis). Retina Today 2, 27-31 (2007).
59. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem. 13(27), 3307-3317 (2006).
60. Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with-somatostatin analogues. Expert Opin. Investig. Drugs 16(1), 73-82 (2007).
61. Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev. Ophthalmol. 39, 111-121 (2007).
62. Gao BB, Clermont A, Rook S et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 13(2). 181-188 (2007).
63. Fletcher EL, Phipps JA, Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. Clin. Exp. Optom. 88(3), 132-145 (2005).
64. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br. J. Ophthalmol. 89(1), 74-80 (2005).